Literature DB >> 18937612

New perspectives for the treatment options in spinal cord injury.

Hari Shanker Sharma1.   

Abstract

Spinal cord injury (SCI) is a serious clinical disorder that leads to lifetime disability for which no suitable therapeutic agents are available so far. Further research is needed to understand the basic mechanisms of spinal cord pathology that results in permanent disability and poses a heavy burden on our society. In the past, a lot of effort was placed on improving functional outcome with the help of various therapeutic agents, however less attention has been paid on the development and propagation of spinal cord pathology over time. Thus, it is still unclear whether improvement of functional outcome is related to spinal cord pathology or vice versa. Few drugs are able to influence functional outcome without having any improvement on cord pathology. Some drugs, however, can lessen cord pathology but fail to influence the functional outcome. The goal of future treatment options for SCI is therefore to find suitable new drugs or a combination of existing drugs and to use various cellular transplants, neurotrophic factors, myelin-inhibiting factors, tissue engineering and nano-drug delivery to improve both the functional and the pathological outcome in the inured patient. This review deals with the key aspects of the latest treatments for SCI and suggests some possible future therapeutic measures to enhance healthcare in clinical situations.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18937612     DOI: 10.1517/14656566.9.16.2773

Source DB:  PubMed          Journal:  Expert Opin Pharmacother        ISSN: 1465-6566            Impact factor:   3.889


  8 in total

1.  Blood-CNS barrier, neurodegeneration and neuroprotection: recent therapeutic advancements and nano-drug delivery.

Authors:  Hari S Sharma
Journal:  J Neural Transm (Vienna)       Date:  2011-01       Impact factor: 3.575

2.  Melatonin prevents blood vessel loss and neurological impairment induced by spinal cord injury in rats.

Authors:  Yingli Jing; Fan Bai; Hui Chen; Hao Dong
Journal:  J Spinal Cord Med       Date:  2016-10-13       Impact factor: 1.985

3.  Nanowired Delivery of Growth Hormone Attenuates Pathophysiology of Spinal Cord Injury and Enhances Insulin-Like Growth Factor-1 Concentration in the Plasma and the Spinal Cord.

Authors:  Dafin F Muresanu; Aruna Sharma; José V Lafuente; Ranjana Patnaik; Z Ryan Tian; Fred Nyberg; Hari S Sharma
Journal:  Mol Neurobiol       Date:  2015-07-01       Impact factor: 5.590

4.  Nanoparticles Exacerbate Both Ubiquitin and Heat Shock Protein Expressions in Spinal Cord Injury: Neuroprotective Effects of the Proteasome Inhibitor Carfilzomib and the Antioxidant Compound H-290/51.

Authors:  Hari S Sharma; Dafin F Muresanu; Jose V Lafuente; Per-Ove Sjöquist; Ranjana Patnaik; Aruna Sharma
Journal:  Mol Neurobiol       Date:  2015-07-01       Impact factor: 5.590

Review 5.  Early microvascular reactions and blood-spinal cord barrier disruption are instrumental in pathophysiology of spinal cord injury and repair: novel therapeutic strategies including nanowired drug delivery to enhance neuroprotection.

Authors:  Hari Shanker Sharma
Journal:  J Neural Transm (Vienna)       Date:  2010-12-16       Impact factor: 3.575

Review 6.  Spinal cord injury: a review of current therapy, future treatments, and basic science frontiers.

Authors:  Abhay K Varma; Arabinda Das; Gerald Wallace; John Barry; Alexey A Vertegel; Swapan K Ray; Naren L Banik
Journal:  Neurochem Res       Date:  2013-03-06       Impact factor: 3.996

7.  Behavioral and Histopathological Study of Changes in Spinal Cord Injured Rats Supplemented with Spirulina platensis.

Authors:  Izzuddin Aziz; Muhammad Danial Che Ramli; Nurul Suraya Mohd Zain; Junedah Sanusi
Journal:  Evid Based Complement Alternat Med       Date:  2014-07-24       Impact factor: 2.629

8.  The role of IL-17 promotes spinal cord neuroinflammation via activation of the transcription factor STAT3 after spinal cord injury in the rat.

Authors:  Shaohui Zong; Gaofeng Zeng; Ye Fang; Jinzhen Peng; Yong Tao; Keke Li; Jingmin Zhao
Journal:  Mediators Inflamm       Date:  2014-04-30       Impact factor: 4.711

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.